
SYMBIOTECSymbiotec Pharmalab Ltd.
Symbiotec Pharmalab Q2 FY27 Results: Consolidated Net Profit ₹51.72 Crore on Total Income of ₹280 Crore
Symbiotec Pharmalab (NSE: SYMBIOTEC) reported consolidated total income of ₹280.04 crore and net profit of ₹51.72 crore for the quarter ended 30 Sep 2026, and standalone total income of ₹240.25 crore and net profit of ₹48.54 crore, it said in a filing on 05 Nov 2026.
- Earnings
- Pharmaceuticals